Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:22 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
NCT06566092 · Iovance Biotherapeutics, Inc. · PHASE1 · terminated · last registry update 2026-10-16 · Rhabdomyosarcoma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “After reviewing the available safety and efficacy data to date, Iovance has made the decision to conclude all remaining participant visits.” | – | Registry record, Iovance Biotherapeutics, Inc. |
Also happening at the time. Not shown to be a cause.
No drug target was found for this trial's interventions, so there is no same-target timeline.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision